117 S3478 IS: Generating Antibiotic Incentives Now Through Opening Opportunities to Leverage Science Act of 2022 U.S. Senate 2022-01-11 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

II117th CONGRESS2d SessionS. 3478IN THE SENATE OF THE UNITED STATESJanuary 11 (legislative day, January 10), 2022Mr. Casey (for himself, Mr. Cassidy, and Mr. Murphy) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and PensionsA BILLTo provide for the designation of biological products as qualified infectious disease products.

1.

Short title

This Act may be cited as the Generating Antibiotic Incentives Now Through Opening Opportunities to Leverage Science Act of 2022 or the GAIN TOOLS Act of 2022.

2.

Expanding qualified infectious disease products to include biological products

(a)

In general

Section 505E of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355f) is amended—(1)in subsection (c)—(A)in paragraph (2), by striking ; or and inserting ;;(B)in paragraph (3), by striking the period and inserting ; or; and(C)by adding at the end the following:(4)an application pursuant to section 351(a) of the Public Health Service Act.;(2)in subsection (d)(1), by inserting of this Act or section 351(a) of the Public Health Service Act after section 505(b); and(3)by amending subsection (g) to read as follows:(g)

Qualified infectious disease product

The term qualified infectious disease product means a drug or biological product for human use that—(1)is—(A)an antibacterial or antifungal drug; or(B)a biological product that acts directly on bacteria or fungi or on substances produced by such bacteria or fungi; and (2)is intended to treat a serious or life-threatening infection, including such an infection caused by—(A)an antibacterial or antifungal resistant pathogen, including novel or emerging infectious pathogens; or (B)qualifying pathogens listed by the Secretary under subsection (f)..(b)

Priority review

Section 524A(a) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360n–1(a)) is amended by inserting of this Act, or section 351(a) of the Public Health Service Act, that requires clinical data (other than bioavailability studies) to demonstrate safety or effectiveness before the period.